Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1: multi-institutional retrospective analysis
Open Access
- 13 October 2011
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Gastric Cancer
- Vol. 15 (3), 245-251
- https://doi.org/10.1007/s10120-011-0101-x
Abstract
It is unclear whether S-1 plus cisplatin is effective for patients with recurrent gastric cancer after adjuvant S-1 chemotherapy.Keywords
This publication has 27 references indexed in Scilit:
- Survival and prognosticators of gastric cancer that recurs after adjuvant chemotherapy with S-1Gastric Cancer, 2011
- Effect of S-1 Adjuvant Chemotherapy on Survival following Recurrence and Efficacy of First-Line Treatment in Recurrent Gastric CancerChemotherapy, 2010
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Activity of S-1 in Advanced or Recurrent Gastric Cancer Patients after Failure of Prior Chemotherapy, Including Irinotecan + Cisplatin or Fluorouracil (Except S-1)Japanese Journal of Clinical Oncology, 2009
- Chemotherapy for Gastric Cancer that Recurs After Adjuvant Chemotherapy with S-1Japanese Journal of Clinical Oncology, 2008
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trialThe Lancet Oncology, 2008
- Capecitabine and Oxaliplatin for Advanced Esophagogastric CancerThe New England Journal of Medicine, 2008
- Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral FluoropyrimidineThe New England Journal of Medicine, 2007
- Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study GroupJournal of Clinical Oncology, 2006
- Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer patientsEuropean Journal of Cancer, 1998